Back to results
US 2022/0304984 A1Published application
Amino acid transport inhibitors and the uses thereof
AssigneeVanderbilt University
InventorsH. Charles Manning, Michael Schulte
Life of this patent
Estimating the term…
Abstract
These compounds are glutamine transporter inhibitors, e.g., alanine, serine, cysteine-preferring transporter 2 (ASCT2) inhibitors. Glutamine transporter inhibitors are useful to treat a variety of diseases, disorders, or conditions including cancer.
Claims33
A compound of Formula I:
- wherein:
- R is selected from the group consisting of hydrogen, C1-C4 alkyl, and aralkyl;
- E is selected from the group consisting of ═C(R5)—, ═C(R1a)—, and ═N—;
- E1 is selected from the group consisting of ═C(R5)—, ═C(R1a)—, and ═N—;
- with the proviso that one of E or E1 is ═C(R5)— and the other is ═C(R1a)— or ═N—;
- E2 is selected from the group consisting of ═C(R1b)— and ═N—;
- E3 is selected from the group consisting of ═C(R1c)— and ═N—;
- E4 is selected from the group consisting of ═C(R1d)— and ═N—;
- R1a, R1b, R1c, and R1d are each independently selected from the group consisting of hydrogen, halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, and C1-C4 alkoxy;
- R5 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
- Q is selected from the group consisting of:
- with the proviso that the bond designated with an “*” is attached to —C(═O)OR;
- G is selected from the group consisting of —S—, —O—, and —N(R2a)—;
- G1 is selected from the group consisting of ═C(R3a)— and ═N—;
- G2 is selected from the group consisting of ═C(R3b)— and ═N—;
- A is selected from the group consisting of ═C(R4a)— and ═N—;
- A1 is selected from the group consisting of ═C(R4b)— and ═N—;
- A2 is selected from the group consisting of ═C(R4c)— and ═N—;
- R2a is selected from the group consisting of hydrogen and C1-C4 alkyl;
- R3a and R3b are independently selected from the group consisting of hydrogen, hydroxy, halo, C1-C4 alkyl, and C1-C4 haloalkyl;
- and
- R4a, R4b, and R4c are each independently selected from the group consisting of hydrogen, halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, and C1-C4 alkoxy,
- or a pharmaceutically acceptable salt or solvate thereof,
- with the proviso that the compound is not:
- 5-([1,1′-biphenyl]-4-yl)-6-chloro-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid;
- 1-methyl-3-((4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)oxy)-1H-pyrazole-5-carboxylic acid;
- or
- 3-((4-(4-phenyl-1H-indol-1-yl)benzyl)oxy)isoxazole-5-carboxylic acid.
25 more elements
27-43. (canceled)
45-50. (canceled)
54-56. (canceled)
Dependencies are inferred from the claim text.